Tissera (TSSR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tissera (TSSR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: alenor	3/8/2007 12:13:27 PM
	Read Replies (1) of 23

One more from Tissera web site: "Tissera, Inc. (OTCBB: TSSR – News) reports that it has completed an additional equity financing round amounting to a gross of $1,650,000 before related expenses. This sum was raised from existing Tissera institutional investors. The current proceeds are earmarked for the continuing support and enhancing of the ongoing preclinical studies being performed on primate models of type I (insulin-dependent) diabetes mellitus, as a preparation for the initiation of human clinical studies on diabetic patients. The research activity of the company is performed at the Weizmann Institute of Science. Amos Eiran, Tissera's Chairman & CEO adds: "We are extremely pleased with the success of this additional fund raising round, which is a strong expression of the investors' belief in our company. The proceeds raised will be used to support the completion of the preclinical studies on primate diabetic models, designed to demonstrate the curative potential of the company's proprietary transplantation technology. Those studies, if successfully concluded as we hope and expect, will enable us to apply for the authorization to start human clinical studies on type I diabetes patients." Still looking for more information on this one. News could be soon? alen

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next